Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.
IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against the rest of the market.
Decades of market research shows that the best-performing stocks typically have an RS Rating of over 80 as they begin their largest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Biohaven Stock A Buy?
Biohaven stock recently reclaimed its 200-day moving average and building the right side of a saucer-shaped base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The biotech firm showed 0% EPS growth in its most recent report, while sales growth came in at 0%.
Biohaven stock earns the No. 254 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, United Therapeutics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
